Today: 8 June 2026
SLB stock slips after RESMAN deal closes as Wall Street turns to earnings
15 January 2026
1 min read

SLB stock slips after RESMAN deal closes as Wall Street turns to earnings

New York, Jan 15, 2026, 15:08 EST — Regular session

Shares of SLB slipped 0.5% to $46.72 by 3:08 p.m. EST on Thursday, following news that the oilfield services firm finalized its acquisition of reservoir-monitoring expert RESMAN Energy Technology. The stock fluctuated between $46.11 and $46.89, with roughly 10.6 million shares changing hands.

The RESMAN deal matters because it focuses on the work producers fund when they want to squeeze more oil and gas from existing wells. SLB has said RESMAN’s wireless reservoir surveillance and tracer technologies will speed up how quickly operators detect underground conditions and tweak production.

Another area seeing strong demand is well clean-up, where SLB recently landed a new contract. Archer, partnering with SLB, secured an integrated plug-and-abandonment deal from Equinor for three wells on the Titan platform, Archer said, describing it as a project that “builds on our momentum.” Plug and abandonment, or P&A, involves sealing and decommissioning old wells. Archer

Archer outlined that the scope covers project management, well engineering, a compact workover rig, coiled tubing and wireline services, plus downhole P&A technologies.

Analysts are bracing for SLB’s upcoming earnings, though many warn the trade is crowded. Keith Mackey of RBC Capital bumped his price target on SLB from $43 to $51, maintaining an “Outperform” rating. Still, he flagged that matching the recent surge in optimism around oilfield services could prove “challenging” for both results and guidance. TipRanks

RBC boosted its price targets for several names in the group during its quarterly preview, including Halliburton and Baker Hughes. The target for Halliburton jumped to $36 from $31, while Baker Hughes saw its target rise to $57 from $54. Both stocks kept their outperform ratings, according to MT Newswires.

SLB is positioning RESMAN more as a production and recovery upgrade than a flashy headline deal. “This acquisition enhances SLB’s ability to deliver differentiated reservoir surveillance and production optimization solutions,” said Paul Sims, president of SLB’s Production Systems unit. MarketScreener

But bolt-on tech still demands smooth integration, and the benefits often don’t show up every quarter. If operators pull back on spending or push off projects, even basic monitoring and optimization can falter. The market usually penalizes anything that feels like a “good story, later numbers” scenario.

SLB’s next big event comes Jan. 23, with Q4 and full-year earnings dropping before the open and a conference call set for 9:30 a.m. ET. Investors want clear signals on activity levels and margins — plus an early check on whether RESMAN is making an impact in actual orders, not just in presentations.

Stock Market Today

  • S&P 500, Dow Futures Dip Amid Iran's First Missile Attack on Israel Since April
    June 8, 2026, 9:24 AM EDT. S&P 500 and Dow Jones futures dipped as Iran launched its first missile attack on Israel since April, escalating geopolitical tensions. The attack threatens fragile ceasefire efforts between Tehran and Washington. Meanwhile, President Trump reportedly urged Israeli Prime Minister Netanyahu to avoid retaliation, aiming to preserve ongoing Iran nuclear deal talks. The tech-heavy Nasdaq Composite suffered its steepest drop in 14 months, losing over 1,000 points last Friday, closing 4.18% lower. Oil futures rose amid Middle East tensions, adding pressure to global markets. ETFs tracking major indexes showed mixed moves: SPDR S&P 500 ETF and Invesco QQQ Trust edged higher, Dow Jones ETF traded lower, and long-term Treasury bond ETF fell slightly. This geopolitical uncertainty compounds market challenges following a sharp tech sell-off, leaving investors cautious as they monitor evolving developments in the region.

Latest articles

Tango Therapeutics Stock Surges After Cancer Drug Shows 92% Response Rate

Tango Therapeutics Stock Surges After Cancer Drug Shows 92% Response Rate

8 June 2026
Tango shares soared up to 48% in premarket trading after reporting a 92% objective response rate and 90% six-month progression-free survival in a 12-patient pancreatic cancer trial, with plans to advance the vopimetostat-daraxonrasib combo to Phase 3 testing in first-line MTAP-deleted pancreatic cancer.
Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

8 June 2026
Plug Power rose 2.95% to $3.31 in Monday pre-market trading after a $39.2 million federal tax credit sale tied to its St. Gabriel hydrogen facility, as investors await CEO Jose Luis Crespo’s June 11 update on liquidity and asset sales amid ongoing losses and a recent 10.69% stock drop.
ABAT Shares Jump on DOE’s $115M Lithium Grant Return

ABAT Shares Jump on DOE’s $115M Lithium Grant Return

8 June 2026
American Battery Technology Co shares soared 29.58% to $4.03 premarket after the U.S. Department of Energy fully reinstated a $115 million grant for its Nevada lithium refinery, restoring federal funding for the Tonopah Flats Lithium Project with no change to awarded funds or milestones, though risks remain from permitting, financing, and volatile lithium prices.
NANO Nuclear Stock Bounces, Investors Eye What’s Next

NANO Nuclear Stock Bounces, Investors Eye What’s Next

8 June 2026
NANO Nuclear Energy jumped 7.8% to $25.40 in premarket trading after a 9.9% Friday drop, as traders weighed fresh insider sales filings and recent regulatory progress on its KRONOS microreactor project; the company held $568.7 million in cash as of March 31, but faces sector-wide volatility and execution risks.
POET Technologies stock climbs before the bell as call-option volume spikes
Previous Story

POET Technologies stock climbs before the bell as call-option volume spikes

Philip Morris stock edges up after PMI flags $20B+ U.S. investment push, FDA ZYN review ahead
Next Story

Philip Morris stock edges up after PMI flags $20B+ U.S. investment push, FDA ZYN review ahead

Go toTop